This week's roundup of Houston innovators includes Allie Danziger of Ampersand, Wesley Okeke of CUBIO, and Libby Covington of The Craig Group. Courtesy photos

Editor's note: In this week's roundup of Houston innovators to know, I'm introducing you to three local innovators across industries — from health tech to future of work — recently making headlines in Houston innovation.


Allie Danziger, co-founder and CEO of Ampersand Professionals

Allie Danziger, is bridging the gap between the next generation — and their future employers. Photo courtesy of Ampersand

Allie Danziger has established herself as an expert in the future of work and all things Gen Z in the workplace. The founder of an internship matching and training platform called Ampersand, she's contributed numerous articles on related topics, including "The Great Resignation," which is affecting the workforce across industries. It's also something her platform can address, as she explains on the Houston Innovators Podcast.

"When someone leaves, other people take on that work. If you don't hire proper support for the people still there, you see the trickle. You see more and more people leave, because they are just burnt out," Danziger says. "By hiring interns or entry-level support, it shows the employees still there that you've got them."

Danziger shares more on Ampersand's future and navigating the Gen Z workforce on the podcast. Click here to read more and stream the episode.

Wesley Okeke, CEO of CUBIO Innovation Center

Wesley Okeke has established some much-needed new lab space in the Texas Medical Center. Photo courtesy

Look alive, Houston biotech innovators. CUBIO Innovation Center has some new space available for you. What originated as mostly coworking space, CUBIO has pivoted to provide more lab space for early stage biotech startups. The latest edition to CUBIO in the Texas Medical Center? A brand new wet lab.

“We have all the necessary equipment for a fully functioning biotech lab,” Okeke tells InnovationMap.

"For those working with cell culture, the dry lab provides almost no resources or infrastructure for you to build it out," he continues. "A wet lab brings in the necessary equipment and environment to be successful in developing pharmaceuticals, drug delivery devices, whatever you need in the biotech space.” Click here to read more.

Libby Covington, partner at The Craig Group

What should Houston startups know about marketing? Photo courtesy

How should startups be marketing themselves to venture capitalists? Libby Covington has some advice in a guest article for InnovationMap — from making your marketing plan and catering specifically to VCs.

"It is important to focus on efficient top line revenue growth as a business grows and scales," she writes. "Digital marketing is an important part of the overall growth plan, and should not be overlooked. The clock starts ticking on profitability growth once a business owner partners with investors. Make sure your business has an effective plan to meet the goals set out." Click here to read more.

Houston has some much-needed new lab space in the Texas Medical Center. Photo courtesy of CUBIO

Exclusive: Houston biotech coworking spot expands with new wet lab space

ready to rent

While Houston has been recognized as an emerging hub for life sciences, access to lab space is a huge factor in that equation — and one where the city has room for improvement.

CUBIO Innovation Center, located in the heart of the Texas Medical Center, has witnessed that first hand. First opening as a larger coworking concept, CEO Wesley Okeke says it was the smaller lab space that was booked every day. CUBIO pivoted and redistributed their operations to offer more dry lab space to its tenants. Now, the organization is ready to reach the next stage by introducing a new wet lab that opens doors for biotech innovators who need specific infrastructure, equipment, and environment.

“We have all the necessary equipment for a fully functioning biotech lab,” Okeke tells InnovationMap.

"For those working with cell culture, the dry lab provides almost no resources or infrastructure for you to build it out," he continues. "A wet lab brings in the necessary equipment and environment to be successful in developing pharmaceuticals, drug delivery devices, whatever you need in the biotech space.”

The new space can support 15 early stage biotech startups. Photo courtesy of CUBIO

Most of Houston's wet lab space is housed in academic or health care institutions. Getting into those labs can be competitive and complicated, especially when it comes to intellectual property. CUBIO wanted to offer an alternative for early stage biotech teams working on a tight budget and not looking for a long-term commitment.

“When it comes to finding wet lab space, it’s almost nonexistent," Okeke says. "There are a very few out there, but there are very few considering the ecosystem of biotech research in Houston.”

Okeke says CUBIO has seen interest from out-of-town startups looking for space — and not being able to find it without building it themselves.

"We have created what we call lab offices, which could be individual labs, but we have a main area with all our equipment," he says.

And the new space has room to grow. Right now, CUBIO can support 15 companies in its space. With potential to expand on its current sixth floor and to the fifth floor as well, that could grow to a capacity of 50 companies.

Monthly rent starts at $400 for a workbench and up to $950 for a private office and a workbench in the lab. All of CUBIO's memberships options include incubation support from the team and its network of mentors and experts.

“My personal dream and vision is to help these startups in Houston get what they need — get the resources they need and the support they need to launch," Okeke says.

The CUBIO team offers incubation support for its tenant startups. Photo courtesy of CUBIO

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston geothermal unicorn Fervo officially files for IPO

going public

Fervo Energy has officially filed for IPO.

The Houston-based geothermal unicorn filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission on April 17 to list its Class A common stock on the Nasdaq exchange. Fervo intends to be listed under the ticker symbol "FRVO."

The number and price of the shares have not yet been determined, according to a news release from Fervo. J.P. Morgan, BofA Securities, RBC Capital Markets and Barclays are leading the offering.

The highly anticipated filing comes as Fervo readies its flagship Cape Station geothermal project to deliver its first power later this year

"Today, miles-long lines for gasoline have been replaced by lines for electricity. Tech companies compete for megawatts to claim AI market share. Manufacturers jockey for power to strengthen American industry. Utilities demand clean, firm electricity to stabilize the grid," Fervo CEO Tim Latimer shared in the filing. "Fervo is prepared to serve all of these customers. Not with complex, idiosyncratic projects but with a simplified, standardized product capable of delivering around-the-clock, carbon-free power using proven oil and gas technology."

Fervo has been preparing to file for IPO for months. Axios Pro first reported that the company "quietly" filed for an IPO in January and estimated it would be valued between $2 billion and $3 billion.

Fervo also closed $421 million in non-recourse debt financing for the first phase of Cape Station last month and raised a $462 million Series E in December. The company also announced the addition of four heavyweights to its board of directors last week, including Meg Whitman, former CEO of eBay, Hewlett-Packard, and Spring-based HPE.

Fervo reported a net loss of $70.5 million for the 2025 fiscal year in the S-1 filing and a loss of $41.1 million in 2024.

Tracxn.com estimates that Fervo has raised $1.12 billion over 12 funding rounds. The company was founded in 2017 by Latimer and CTO Jack Norbeck.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

New UT Austin med center, anchored by MD Anderson, gets $1 billion gift

Future of Health

A donation announced Tuesday, April 21, breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release.

The release also records "significant support" for undergraduate scholarships, student housing, and the Texas Advanced Computing Center for supercomputing research.

Both the new research campus and the UT Dell Medical Center will integrate advanced computing into their research and practices. At the medical center, the university hopes that will lead to "earlier detection, more precise and personalized care, and better health outcomes." The University of Texas MD Anderson Cancer Center will also be integrated into the new medical center.

That comes with a numeric goal measured in 10s: raise $10 billion and rank among the top 10 medical centers in the U.S., both in the next decade.

In the shorter term, the university will break ground on the medical center with architecture firm Skidmore, Owings & Merrill (SOM) "later this year."

“UT Austin, where Dell Technologies was founded from a dorm room, has always been a place where bold ideas become real-world impact,” said Michael and Susan Dell in a joint statement.

They continued, “What makes this moment so meaningful is the opportunity to build something that brings every part of the journey together — from how students learn, to how discoveries are made, to how care reaches families. By bringing together medicine, science and computing in one campus designed for the AI era, UT can create more opportunity, deliver better outcomes, and build a stronger future for communities across Texas and beyond.”

This is the second major gift this year for the planned multibillion-dollar medical center. In January, Tench Coxe, a former venture capitalist who’s a major shareholder in chipmaking giant Nvidia, and Simone Coxe, co-founder and former CEO of the Blanc & Otus PR firm, contributed $100 million$100 million.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

Alzheimer’s research

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March.

Dr. Ryan S. Dhindsa is an assistant professor of pathology & immunology at Baylor and a principal investigator at Texas Children’s Duncan Neurological Research Institute (Duncan NRI). He hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation.

“It is an honor to receive this support from the Cure One, Cure Many Award. Viral infections are emerging as a major, underappreciated driver of Alzheimer's disease, and this award will allow our team to conduct the most comprehensive screen of viral exposures and host genetics in Alzheimer's to date, spanning over a million individuals,” Dhindsa said in a news release. “Our goal is to identify which viruses matter most, why some people are more vulnerable than others, and ultimately move the field closer to new therapeutic strategies for patients.”

Roughly 150 million people worldwide will suffer from Alzheimer’s by 2050, making it the most common cause of dementia in the world. Despite this, scientists are still at a loss as to what exactly causes it.

Dhindsa’s research is part of a new range of theories that certain viral infections may trigger Alzheimer’s. His team will take a two-fold approach. First, they will analyze the medical records of more than a million individuals looking for patterns. Second, they will analyze viral DNA in stem cell-derived brain cells to see how the infections could contribute to neurological decay. The scale of the genomic data gathering is unprecedented and may highlight a link that traditional studies have missed.

Also joining the project are Dr. Caleb Lareau of Memorial Sloan Kettering Cancer Center and Dr. Artem Babaian of the University of Toronto. Should a link be found, it would open the door to using anti-virals to prevent or treat Alzheimer’s.